A
Alan E. Wakeling
Researcher at AstraZeneca
Publications - 12
Citations - 2677
Alan E. Wakeling is an academic researcher from AstraZeneca. The author has contributed to research in topics: Antiestrogen & Tamoxifen. The author has an hindex of 12, co-authored 12 publications receiving 2644 citations. Previous affiliations of Alan E. Wakeling include AkzoNobel.
Papers
More filters
Journal Article
A potent specific pure antiestrogen with clinical potential.
TL;DR: The properties of ICI 182,780 identify this pure antiestrogen as a prime candidate with which to evaluate the potential therapeutic benefits of complete estrogen withdrawal in endocrine-responsive human breast cancer.
Journal ArticleDOI
ICI 182,780, a new antioestrogen with clinical potential
Alan E. Wakeling,Jean Bowler +1 more
TL;DR: ICI 182,780 provides the opportunity to evaluate clinically the potential therapeutic benefits of complete blockade of oestrogen effects in endocrine-responsive human breast cancer.
Journal Article
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.
John F.R. Robertson,Robert Ian Nicholson,Nigel J Bundred,Elizabeth Anderson,Zenon Rayter,Mitchell Dowsett,J.N. Fox,Julia Margaret Wendy Gee,Alan Webster,Alan E. Wakeling,Charles A. Morris,Michael Dixon +11 more
TL;DR: Reductions in tumor cell proliferative activity (as indicated by Ki67LI) show that ICI 182,780 is likely to have antitumor activity in the clinical setting, and short-term exposure to ICI182,780 reduces the ERalpha in breast tumor cells in a dose-dependent manner by down-regulating ER protein concentration.
MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
Nils Brünner,Thomas Frandsen,Thomas Frandsen,Claus Holst-Hansen,Mian Bei,Erik W. Thompson,Alan E. Wakeling,Marc E. Lippman,Robert Clarke +8 more
TL;DR: The data suggest that some breast cancer patients who acquire resistance to tamoxifen may not develop cross-resistance to treatment with steroidal antiestrogens.
Journal Article
MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780
Nils Brünner,Thomas Frandsen,Thomas Frandsen,Claus Holst-Hansen,Mian Bei,Erik W. Thompson,Alan E. Wakeling,Marc E. Lippman,Robert Clarke +8 more
TL;DR: A stepwise selection of the hormone-independent human breast cancer variant MCF-7/LCC1 against 4-hydroxytamoxifen produced a stable resistant population designated MCF7/LC2.